Vosaroxin for acute myeloid leukemia
The treatment of acute myeloid leukemia (AML) in adults has not significantly changed in the past five decades. Despite the availability of effective induction chemotherapy, most patients eventually relapse. Relapsed or refractory AML, and AML in patients 60 years of age and older are particularly d...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| التنسيق: | article |
| منشور في: |
2014
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/6262 http://dx.doi.org/10.4155/CLI.13.126 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://www.openaccessjournals.com/articles/vosaroxin-for-acute-myeloid-leukemia.pdf |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513478951174144 |
|---|---|
| author | El-Amm, Joelle |
| author2 | Tabbara, Imad A. |
| author2_role | author |
| author_facet | El-Amm, Joelle Tabbara, Imad A. |
| author_role | author |
| dc.creator.none.fl_str_mv | El-Amm, Joelle Tabbara, Imad A. |
| dc.date.none.fl_str_mv | 2014 2017-09-25T08:30:27Z 2017-09-25T08:30:27Z 2017-09-25 |
| dc.identifier.none.fl_str_mv | 2041-6806 http://hdl.handle.net/10725/6262 http://dx.doi.org/10.4155/CLI.13.126 El-Amm, J., & Tabbara, I. A. (2014). Vosaroxin for acute myeloid leukemia. Clinical Investigation, 4(2), 147-152. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://www.openaccessjournals.com/articles/vosaroxin-for-acute-myeloid-leukemia.pdf |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | Clinical investigation |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Vosaroxin for acute myeloid leukemia |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | The treatment of acute myeloid leukemia (AML) in adults has not significantly changed in the past five decades. Despite the availability of effective induction chemotherapy, most patients eventually relapse. Relapsed or refractory AML, and AML in patients 60 years of age and older are particularly difficult to treat and have poor prognosis hence the need for novel therapies. Vosaroxin is a novel first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. Vosaroxin was shown in preclinical studies to be a potent antileukemia agent with unique features that overcome common mechanisms of resistance to standard therapy. Vosaroxin as single agent or in combination with cytarabine showed promising tolerability and activity in Phase I and II studies. The combination of vosaroxin and cytarabine is currently being studied in the Phase III VALOR trial that will define the role of vosaroxin in first relapsed or refractory AML. This review summarizes the preclinical and clinical studies of vosaroxin in AML. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_2cff2a0eea87ce1fd46c2fef8c0d5e6c |
| identifier_str_mv | 2041-6806 El-Amm, J., & Tabbara, I. A. (2014). Vosaroxin for acute myeloid leukemia. Clinical Investigation, 4(2), 147-152. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/6262 |
| publishDate | 2014 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Vosaroxin for acute myeloid leukemiaEl-Amm, JoelleTabbara, Imad A.The treatment of acute myeloid leukemia (AML) in adults has not significantly changed in the past five decades. Despite the availability of effective induction chemotherapy, most patients eventually relapse. Relapsed or refractory AML, and AML in patients 60 years of age and older are particularly difficult to treat and have poor prognosis hence the need for novel therapies. Vosaroxin is a novel first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. Vosaroxin was shown in preclinical studies to be a potent antileukemia agent with unique features that overcome common mechanisms of resistance to standard therapy. Vosaroxin as single agent or in combination with cytarabine showed promising tolerability and activity in Phase I and II studies. The combination of vosaroxin and cytarabine is currently being studied in the Phase III VALOR trial that will define the role of vosaroxin in first relapsed or refractory AML. This review summarizes the preclinical and clinical studies of vosaroxin in AML.PublishedN/A2017-09-25T08:30:27Z2017-09-25T08:30:27Z20142017-09-25Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article2041-6806http://hdl.handle.net/10725/6262http://dx.doi.org/10.4155/CLI.13.126El-Amm, J., & Tabbara, I. A. (2014). Vosaroxin for acute myeloid leukemia. Clinical Investigation, 4(2), 147-152.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttp://www.openaccessjournals.com/articles/vosaroxin-for-acute-myeloid-leukemia.pdfenClinical investigationinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/62622021-03-19T10:03:28Z |
| spellingShingle | Vosaroxin for acute myeloid leukemia El-Amm, Joelle |
| status_str | publishedVersion |
| title | Vosaroxin for acute myeloid leukemia |
| title_full | Vosaroxin for acute myeloid leukemia |
| title_fullStr | Vosaroxin for acute myeloid leukemia |
| title_full_unstemmed | Vosaroxin for acute myeloid leukemia |
| title_short | Vosaroxin for acute myeloid leukemia |
| title_sort | Vosaroxin for acute myeloid leukemia |
| url | http://hdl.handle.net/10725/6262 http://dx.doi.org/10.4155/CLI.13.126 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://www.openaccessjournals.com/articles/vosaroxin-for-acute-myeloid-leukemia.pdf |